We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Louis Navellier is a prominent American investor, author, and financial analyst, best known for his quantitative approach to ...

Piper Sandler reiterated its Overweight rating on Amgen (NASDAQ:AMGN) shares, maintaining a price target of $310.00. The company, which boasts a "GOOD" overall financial health score according to ...

The Food and Drug Administration approved Amgen Inc ‘s AMGN Lumakras (sotorasib) in combination with Vectibix (panitumumab) ...

Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination ...

In our analysis, these 12 brokerage accounts stand out as the best choices for stock trading, due to their low fees, strong platforms and quality customer support. Many, or all, of the products ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $310.00. The ...

Amgen (AMGN) stock in focus as U.S. approval for its lung cancer drug expands for metastatic colorectal cancer. Read more ...

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $268.94 which represents a slight increase of $1.84 or 0.69% from the prior close of $267.1. The stock opened at $269.33 and touched a low ...

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Amgen Inc. closed $79.75 short of its 52-week high ($346.85), which the company achieved on July 25th.